688185 康希诺
已收盘 02-27 15:00:01
资讯
新帖
简况
康希诺：公司的重组肺炎球菌蛋白疫苗PBPV已完成I期临床试验并取得积极初步数据
每日经济新闻 · 02-26 17:52
康希诺：公司的重组肺炎球菌蛋白疫苗PBPV已完成I期临床试验并取得积极初步数据
康希诺2025年度业绩快报：扭亏为盈，归母净利润达2787万元
财中社 · 02-26 16:39
康希诺2025年度业绩快报：扭亏为盈，归母净利润达2787万元
康希诺：ACYW135群脑膜炎球菌多糖结合疫苗适用人群年龄范围扩大
每日经济新闻 · 02-24 16:33
康希诺：ACYW135群脑膜炎球菌多糖结合疫苗适用人群年龄范围扩大
股市必读：1月29日康希诺现1笔折价11.8%的大宗交易 合计成交392.77万元
证券之星 · 01-30
股市必读：1月29日康希诺现1笔折价11.8%的大宗交易 合计成交392.77万元
康希诺：公司以在世界范围内提供预防和治疗感染类疾病的解决方案为己任，已建立了成熟的技术平台
证券日报 · 01-27
康希诺：公司以在世界范围内提供预防和治疗感染类疾病的解决方案为己任，已建立了成熟的技术平台
康希诺(688185.SH)发预盈，预计2025年年度归母净利润2450万元到2900万元
智通财经 · 01-27
康希诺(688185.SH)发预盈，预计2025年年度归母净利润2450万元到2900万元
康希诺跌3.73% 2020年上市募52亿元中信证券保荐
中金财经 · 01-27
康希诺跌3.73% 2020年上市募52亿元中信证券保荐
1月26日康希诺涨11.67%，广发科创板两年定开混合基金重仓该股
证券之星 · 01-26
1月26日康希诺涨11.67%，广发科创板两年定开混合基金重仓该股
智通决策参考︱贵金属热度居高不下 太空新基建概念爆发
智通财经 · 01-26
智通决策参考︱贵金属热度居高不下 太空新基建概念爆发
康希诺：公司不持有磐如生物科技（天津）有限公司的股份
证券日报 · 01-13
康希诺：公司不持有磐如生物科技（天津）有限公司的股份
康希诺：公司将利用搭建的mRNA技术平台拓展更多应用领域
证券日报 · 01-13
康希诺：公司将利用搭建的mRNA技术平台拓展更多应用领域
康希诺：公司的吸附破伤风疫苗的药品注册申请正在正常审核中
证券日报 · 01-13
康希诺：公司的吸附破伤风疫苗的药品注册申请正在正常审核中
每周股票复盘：康希诺（688185）24价肺炎疫苗获临床试验批准
证券之星 · 01-11
每周股票复盘：康希诺（688185）24价肺炎疫苗获临床试验批准
康希诺：2025年公司4款候选产品已获得批准IND/NDA
证券日报 · 01-06
康希诺：2025年公司4款候选产品已获得批准IND/NDA
康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准
证券日报 · 01-06
康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准
康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗
证券日报 · 01-06
康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗
康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症
证券日报 · 01-06
康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症
康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量
证券日报 · 01-06
康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量
康希诺生物获中国国家药监局批准开展PCV24相关临床试验
美股速递 · 01-05
康希诺生物获中国国家药监局批准开展PCV24相关临床试验
康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作
证券日报 · 2025-12-23
康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作
加载更多
公司概况
公司名称：
康希诺生物股份公司
所属行业：
医药制造业
上市日期：
2020-08-13
主营业务：
康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是MCV4、PCV13i、MCV2、Ad5-nCoV、吸入用Ad5-nCoV及XBB.1.5变异株疫苗、Ad5-EBOV。
发行价格：
209.71
{"stockData":{"symbol":"688185","market":"SH","secType":"STK","nameCN":"康希诺","latestPrice":72,"timestamp":1772175601000,"preClose":67.78,"halted":0,"volume":5029426,"delay":0,"changeRate":0.0623,"floatShares":113999999,"shares":247000000,"eps":-0.575,"marketStatus":"已收盘","change":4.22,"latestTime":"02-27 15:00:01","open":68,"high":72.4,"low":67.7,"amount":356000000,"amplitude":0.0693,"askPrice":72.05,"askSize":2,"bidPrice":72,"bidSize":52,"shortable":0,"etf":0,"ttmEps":-0.575,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772415000000},"marketStatusCode":5,"adr":0,"adjPreClose":67.78,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772155800000,1772163000000],[1772168400000,1772175600000]],"highLimit":74.56,"lowLimit":61,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":247043801,"isCdr":false,"pbRate":3.61,"roa":"--","roe":"0.29%","epsLYR":-1.53,"committee":-0.343066,"marketValue":17787000000,"turnoverRate":0.044,"status":0,"afterMarket":{"amount":0,"volume":0,"close":72,"buyVolume":300,"sellVolume":0,"time":1772177637558,"indexStatus":"已收盘 02-27 15:30:00","preClose":67.78},"hkstockBrief":{"symbol":"06185","market":"HK","secType":"STK","nameCN":"康希诺生物","latestPrice":35.48,"timestamp":1772179700009,"preClose":33.18,"halted":0,"volume":1703200,"delay":0,"premium":"-56.85"},"floatMarketCap":8235000000},"requestUrl":"/m/hq/s/688185","defaultTab":"news","newsList":[{"id":"2614115011","title":"康希诺：公司的重组肺炎球菌蛋白疫苗PBPV已完成I期临床试验并取得积极初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2614115011","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614115011?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:52","pubTimestamp":1772099537,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问贵公司肺炎PBPV疫苗研发进展如何？是否已启动Ⅱ期临床实验？预计何时完成?康希诺（688185.SH）2月26日在投资者互动平台表示，公司的重组肺炎球菌蛋白疫苗PBPV已完成I期临床试验并取得积极初步数据，下一阶段研发仍在探讨规划中，如有阶段性进展，公司将及时分享。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602263655438031.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655438031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185","159646"],"gpt_icon":0},{"id":"2614013278","title":"康希诺2025年度业绩快报：扭亏为盈，归母净利润达2787万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614013278","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614013278?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:39","pubTimestamp":1772095189,"startTime":"0","endTime":"0","summary":"2月26日，康希诺（688185/06185）发布公告，2025年度业绩快报显示，公司实现营业总收入约为10.68亿元，同比增长26.18%；归母净利润约为2787万元，成功扭亏为盈。公告指出，公司的营业利润和利润总额均实现扭亏为盈，主要得益于营业总收入的增长和成本控制措施的有效实施。2025年前三季度，康希诺实现收入6.93亿元，归母净利润1444万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655351021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185"],"gpt_icon":0},{"id":"2613032795","title":"康希诺：ACYW135群脑膜炎球菌多糖结合疫苗适用人群年龄范围扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2613032795","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613032795?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:33","pubTimestamp":1771921994,"startTime":"0","endTime":"0","summary":"每经AI快讯，2月24日，康希诺(688185.SH)公告称，公司产品ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）适用人群年龄范围由“3月龄~3周岁（47月龄）儿童”扩大至“3月龄~6周岁（83月龄）儿童”。该疫苗为我国首个脑膜炎球菌四价结合疫苗产品，其适用人群年龄范围的扩大预计将对公司业绩产生积极影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602243652735579.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602243652735579.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","159646","BK0239"],"gpt_icon":0},{"id":"2607037545","title":"股市必读：1月29日康希诺现1笔折价11.8%的大宗交易 合计成交392.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607037545","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607037545?lang=zh_cn&edition=full","pubTime":"2026-01-30 01:30","pubTimestamp":1769707834,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，康希诺报收于69.69元，下跌3.64%，换手率3.5%，成交量4.01万手，成交额2.83亿元。交易信息汇总资金流向1月29日主力资金净流出2249.27万元，占总成交额7.94%；游资资金净流入847.43万元，占总成交额2.99%；散户资金净流入1401.84万元，占总成交额4.95%。大宗交易1月29日康希诺现1笔折价11.8%的大宗交易，合计成交392.77万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000000882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2606824327","title":"康希诺：公司以在世界范围内提供预防和治疗感染类疾病的解决方案为己任，已建立了成熟的技术平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2606824327","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606824327?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:13","pubTimestamp":1769519628,"startTime":"0","endTime":"0","summary":"证券日报网讯1月27日，康希诺在互动平台回答投资者提问时表示，公司以在世界范围内提供预防和治疗感染类疾病的解决方案为己任，已建立了成熟的技术平台，可以针对不同病毒及细菌等的防护需要进行疫苗的开发。公司会持续关注该事件及其发展，在评估相关事件发展情况、开发效率及投入、市场空间及经济效益测算等因素后，如有必要会考虑后续步骤。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601273632481478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2606023652","title":"康希诺(688185.SH)发预盈，预计2025年年度归母净利润2450万元到2900万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606023652","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606023652?lang=zh_cn&edition=full","pubTime":"2026-01-27 17:11","pubTimestamp":1769505112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺(688185.SH)发布2025年年度业绩预告，预计2025年年度实现归属于母公司所有者的净利润为2,450万元到2,900万元，与上年同期相比，将实现扭亏为盈。报告期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗曼海欣®收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控;产销协同进一步优化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属于母公司所有者的净利润为正。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺(688185.SH)发预盈，预计2025年年度归母净利润2450万元到2900万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688185"],"gpt_icon":0},{"id":"2606201794","title":"康希诺跌3.73% 2020年上市募52亿元中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2606201794","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606201794?lang=zh_cn&edition=full","pubTime":"2026-01-27 16:34","pubTimestamp":1769502850,"startTime":"0","endTime":"0","summary":"中国经济网北京1月27日讯 康希诺 今日股价下跌，截至收盘，该股报74.33元，跌幅3.73%。该股目前处于破发状态。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海证券。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260127/31975858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0188","BK0239","LU1997245094.SGD","BK1564","LU1720050803.USD","LU1328615791.USD","BK1521","LU1064131003.USD","LU1064130708.USD","BK1147","LU1655091616.SGD","BK0183","600030","LU2289578879.USD","BK0012","688185","LU1997244956.HKD","LU2495084118.USD","LU0405327148.USD","LU1794554557.SGD","LU1997245177.USD","BK0276","LU2148510915.USD","BK0028","BK0196","BK1516","06030","LU0405327494.USD","LU1255011170.USD"],"gpt_icon":0},{"id":"2606297874","title":"1月26日康希诺涨11.67%，广发科创板两年定开混合基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606297874","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606297874?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:40","pubTimestamp":1769413229,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日康希诺涨11.67%，收盘报77.21元，换手率8.68%，成交量9.93万手，成交额7.48亿元。重仓康希诺的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为广发基金的广发科创板两年定开混合。广发科创板两年定开混合目前规模为2.33亿元，最新净值1.2785，较上一交易日上涨0.61%，近一年上涨62.95%。该公募基金现任基金经理为费逸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600014891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688185","159982"],"gpt_icon":0},{"id":"2606261260","title":"智通决策参考︱贵金属热度居高不下 太空新基建概念爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2606261260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606261260?lang=zh_cn&edition=full","pubTime":"2026-01-26 08:11","pubTimestamp":1769386293,"startTime":"0","endTime":"0","summary":"格陵兰岛事件告一段落，股市也获得喘息的机会，恒指上周探底反弹。本周美联储将公布利率决议。芝商所的“美联储观察”工具显示，市场认为美联储将在1月货币政策会议上保持利率不变的概率已经达到95%。不降息等预期市场已经消化，不会造成负面负面影响。据预测平台Polymarket的数据，截至1月24日，贝莱德高管里克·里德尔当选美联储主席的概率已飙升至54%，而在年初时其当选的概率仅有4%。如果能确定，对市场是一个刺激。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1397072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600699","BK1161","BK1574","06185","BK1583","HHImain","01952","688185","BK1191","513600","00699","BK1144","BK1515","MCHmain","02833","HSImain"],"gpt_icon":0},{"id":"2603680381","title":"康希诺：公司不持有磐如生物科技（天津）有限公司的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680381","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603680381?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:06","pubTimestamp":1768313165,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，康希诺在互动平台回答投资者提问时表示，公司不持有磐如生物科技（天津）有限公司的股份，与其为合作关系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617716055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239","159837"],"gpt_icon":0},{"id":"2603948684","title":"康希诺：公司将利用搭建的mRNA技术平台拓展更多应用领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2603948684","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603948684?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:09","pubTimestamp":1768309778,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，康希诺在互动平台回答投资者提问时表示，公司将在专注做好主营业务的基础上，利用搭建的mRNA技术平台拓展更多应用领域，关注潜在的商业机会，以发挥该技术平台的价值。如有阶段性进展，将及时分享。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617669884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2603686875","title":"康希诺：公司的吸附破伤风疫苗的药品注册申请正在正常审核中","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686875","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603686875?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:36","pubTimestamp":1768304198,"startTime":"0","endTime":"0","summary":"证券日报网讯1月13日，康希诺在互动平台回答投资者提问时表示，公司的吸附破伤风疫苗的药品注册申请正在正常审核中，会根据药审要求及时提供相关资料，以保障审核顺利进行。如有阶段性进展，将及时分享。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617599321.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688185","BK0239","159646"],"gpt_icon":0},{"id":"2602536997","title":"每周股票复盘：康希诺（688185）24价肺炎疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2602536997","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602536997?lang=zh_cn&edition=full","pubTime":"2026-01-11 03:54","pubTimestamp":1768074850,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，康希诺报收于68.69元，较上周的62.85元上涨9.29%。本周关注点公司公告汇总：24价肺炎球菌多糖结合疫苗获临床试验批准。公司公告汇总：该24价肺炎疫苗采用双载体技术，适用于2月龄及以上人群。康希诺H股公告截至2025年12月31日，康希诺生物股份公司H股总数为132,670,900股，A股总数为114,372,901股，法定注册资本为人民币247,043,801元，各项股份均无变动。2025年A股限制性股票激励计划首次授予2,054,600股，但本月未因此发行新股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001241.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0239","688185"],"gpt_icon":0},{"id":"2601890033","title":"康希诺：2025年公司4款候选产品已获得批准IND/NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2601890033","media":"证券日报 ","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601890033?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:32","pubTimestamp":1767706320,"startTime":"0","endTime":"0","summary":"产品获批及研发端，2025年公司4款候选产品已获得批准IND/NDA，以及启动2个新的临床试验，以2026年设置的业绩考核目标A档来看，2026年至少包括5款候选产品获得批准IND、获得批准NDA，以及至少启动2个新的临床试验。目前也是在按既定的研发节奏推进，公司也会和药监、中检院及临床试验合作方等积极沟通，以期顺利推进相应候选产品的研发里程碑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-06/doc-inhfkskh5784664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688185","IND","BK0239"],"gpt_icon":0},{"id":"2601897404","title":"康希诺：公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897404","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601897404?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:08","pubTimestamp":1767704903,"startTime":"0","endTime":"0","summary":"证券日报网1月6日讯，康希诺在接受调研者提问时表示，公司的创新型婴幼儿用联苗DTcP-Hib-MCV4已于2025年2月获得临床试验批准，并于同年12月启动I期临床试验，以评估其在2月龄~6岁人群中接种的安全性及免疫原性，与现有已上市及在研联苗产品形成差异化竞争。该联苗从临床需求的角度出发，考量了婴幼儿所需接种的疫苗品类，预期未来可提升婴幼儿群体接种的便利性和依从性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610446979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2601897400","title":"康希诺：公司产品曼海欣为目前国内唯一获批上市的四价流脑结合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2601897400","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601897400?lang=zh_cn&edition=full","pubTime":"2026-01-06 21:07","pubTimestamp":1767704853,"startTime":"0","endTime":"0","summary":"证券日报网1月6日讯，康希诺在接受调研者提问时表示，公司产品曼海欣?为目前国内唯一获批上市的四价流脑结合疫苗，是定位于中高端婴幼儿疫苗市场的产品，经过近几年的品牌建设、学术推广及市场教育，曼海欣?在国内的市场接受度以及渗透率逐步提升，其销售收入的稳步增长也证实了国内市场对于优质、高端的婴幼儿疫苗的需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610446761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","BK0239","688185"],"gpt_icon":0},{"id":"2601892483","title":"康希诺：利用搭建的mRNA技术平台在治疗领域持续探索更多适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2601892483","media":"证券日报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601892483?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:40","pubTimestamp":1767703205,"startTime":"0","endTime":"0","summary":"证券日报网讯1月6日，康希诺在互动平台回答投资者提问时表示，公司将在专注做好主营业务的基础上，利用搭建的mRNA技术平台在治疗领域持续探索更多适应症，如有阶段性进展，将会及时公布。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610427379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2601643891","title":"康希诺：中检院自2021年4月中旬起不再公布疫苗批签发数量","url":"https://stock-news.laohu8.com/highlight/detail?id=2601643891","media":"证券日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601643891?lang=zh_cn&edition=full","pubTime":"2026-01-06 19:40","pubTimestamp":1767699626,"startTime":"0","endTime":"0","summary":"证券日报网讯1月6日，康希诺在互动平台回答投资者提问时表示，中检院自2021年4月中旬起不再公布疫苗产品的批签发数量，公司会参考同行的信息公示处理方式执行。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601063610380937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159646","BK0239","688185"],"gpt_icon":0},{"id":"1147976460","title":"康希诺生物获中国国家药监局批准开展PCV24相关临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1147976460","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147976460?lang=zh_cn&edition=full","pubTime":"2026-01-05 16:56","pubTimestamp":1767603417,"startTime":"0","endTime":"0","summary":"康希诺生物宣布，公司已正式获得中国国家药品监督管理局（NMPA）的临床试验批准，将启动针对PCV24（24价肺炎球菌结合疫苗）的相关临床研究。\n此次获批标志着康希诺在肺炎疫苗领域的研发取得重要进展，为后续产品上市奠定基础。PCV24疫苗若研发成功，有望为更广泛人群提供肺炎球菌感染的预防保护。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688185"],"gpt_icon":0},{"id":"2593968413","title":"康希诺：公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2593968413","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593968413?lang=zh_cn&edition=full","pubTime":"2025-12-23 21:42","pubTimestamp":1766497324,"startTime":"0","endTime":"0","summary":"证券日报网讯12月23日，康希诺在互动平台回答投资者提问时表示，公司的13价肺炎球菌多糖结合疫苗在按公司发展战略有序推进出海工作，持续与意向国家接触及探讨合作模式，并协同合作方开展临床试验及注册准入等相关工作，以加快公司产品的海外布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599763762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159646","688185"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772180229406,"stockEarnings":[{"period":"1week","weight":0.0607},{"period":"1month","weight":-0.0881},{"period":"3month","weight":-0.0098},{"period":"6month","weight":-0.1778},{"period":"1year","weight":0.0044},{"period":"ytd","weight":0.0784}],"compareEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.2267},{"period":"ytd","weight":0.0448}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"康希诺生物股份公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17290人(较上一季度增加0.19%)","perCapita":"6614股","listingDate":"2020-08-13","address":"天津市东丽区经济技术开发区西区南大街185号西区生物医药园四层401-420","registeredCapital":"24704万元","survey":" 康希诺生物股份公司的主营业务是研发、生产和商业化符合中国及国际标准的创新型疫苗。公司的主要产品是MCV4、PCV13i、MCV2、Ad5-nCoV、吸入用Ad5-nCoV及XBB.1.5变异株疫苗、Ad5-EBOV。","listedPrice":209.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康希诺,688185,康希诺股票,康希诺股票老虎,康希诺股票老虎国际,康希诺行情,康希诺股票行情,康希诺股价,康希诺股市,康希诺股票价格,康希诺股票交易,康希诺股票购买,康希诺股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康希诺(688185)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康希诺(688185)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}